SLC5A2 and Hypoglycemia: Hypoglycemia is the most important risk in T1DM patients with SLC5A2 mutation (by acting as an SGLT2 inhibitor), especially in those <5 years of age, contrary to the studies of Fattah, Evans, and Wolfs Dorf.1, 4, 5